ArticleInternational journal of retina and vitreous2019
Changes in retinal and choriocapillaris density in diabetic patients receiving anti-vascular endothelial growth factor treatment using optical coherence tomography angiography.
Article in International journal of retina and vitreous, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Optical Coherence Tomography Angiography of Macular Perfusion Changes after Anti-VEGF Therapy for Diabetic Macular Edema: A Systematic Review.Journal of diabetes research · 2021Pooled it
- Choroidal Vascular Remodeling and Retinal Response After Aflibercept Loading in Diabetic Macular Edema.Ophthalmology science · 2026Article
- Analysis of correlations between biomarkers assessed with swept-source OCT and OCT angiography in naïve patients with diabetic macular edema treated with aflibercept: a prospective study.International journal of retina and vitreous · 2025Article
- Prospective and dichotomous study of biomarkers with swept-source OCT and OCT-angiography in naive patients with diabetic macular edema.International journal of retina and vitreous · 2025Article
- Macular Ischemia Changes in Patients with Diabetic Macular Edema Treated with Aflibercept and Ranibizumab.Diagnostics (Basel, Switzerland) · 2024Article
- Combining retinal and choroidal microvascular metrics improves discriminative power for diabetic retinopathy.The British journal of ophthalmology · 2023Article
- Optical Coherence Tomography Angiography in Retinal Vascular Disorders.Diagnostics (Basel, Switzerland) · 2023Review
- Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy.Eye (London, England) · 2022Review
- Optic nerve head perfusion changes in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab or photocoagulation: a randomized controlled trial.Medical hypothesis, discovery & innovation ophthalmology journal · 2022Article
- Evaluation of the neuronal and microvascular components of the macula in patients with diabetic retinopathy.Documenta ophthalmologica. Advances in ophthalmology · 2021Article
- Comparison of the Effect of Pan-Retinal Photocoagulation and Intravitreal Conbercept Treatment on the Change of Retinal Vessel Density Monitored by Optical Coherence Tomography Angiography in Patients with Proliferative Diabetic Retinopathy.Journal of clinical medicine · 2021Article
- Microvascular comparison in younger and older patients with retinal vein occlusion analyzed by OCT angiography.BMC ophthalmology · 2021Article
- Quantitative assessment of vascular density in diabetic retinopathy subtypes with optical coherence tomography angiography.BMC ophthalmology · 2021Article
- Effect of anti-VEGF treatment on nonperfusion areas in ischemic retinopathy.International journal of ophthalmology · 2021Review
- Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vitrectomized Eyes with Diabetic Macular Edema.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Association of macular perfusion status with microvascular parameters up to the far periphery in diabetic retinopathy using multimodal imaging.International journal of retina and vitreous · 2020Article
- Evaluation of the different thresholding strategies for quantifying choriocapillaris using optical coherence tomography angiography.Quantitative imaging in medicine and surgery · 2020Article
- Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography.BMC ophthalmology · 2020Article
- Ocular blood flow as a clinical observation: Value, limitations and data analysis.Progress in retinal and eye research · 2020Article
- Identification of microvascular and morphological alterations in eyes with central retinal non-perfusion.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOptical coherence tomography angiography (OCTA) enables detailed, non-invasive assessment of ocular vasculature. This study uses OCTA imaging to evaluate choriocapillaris and retinal capillary perfusion density (CPD) changes in diabetic retinopathy following anti-vascular endothelial growth factor (VEGF) treatment.
methodsRecords of 38 eyes at a single institution were reviewed, grouped as non-diabetic controls (19 eyes), diabetes mellitus patients with diabetic retinopathy (DR, 19 eyes) and macular edema (DME). DR eyes were imaged at baseline, 6-months and 12-months after anti-VEGF treatment. Quantitative analyses assessed CPD of the choriocapillaris and retinal plexus.
resultsDR eyes showed decreased choriocapillaris whole-image CPD (62.6 ± 6.1 vs. 68.4 ± 5.1, p < 0.003), foveal CPD (61.2 ± 7.4 vs. 66.3 ± 9.8, p < 0.014), and parafoveal CPD (61.9 ± 6.6 vs. 68.2 ± 4.8, p < 0.002) at baseline. DR eyes also showed decreased retinal density, including whole-image CPD (46.9 ± 5.1 vs. 50.7 ± 5.6, p < 0.04), foveal CPD (27.6 ± 5.9 vs. 34.1 ± 6.1, p < 0.002), and parafoveal CPD (49.0 ± 5.6 vs. 53.1 ± 6.0, p < 0.011). Following 12 months of anti-VEGF treatment, no changes to retinal or choriocapillaris or CPD were observed. Retinal central subfield thickness decreased (397.1 ± 93.2 µm vs. 294.2 ± 71.5 µm, p < 0.005). Lastly, FAZ area (0.307 ± 0.133 mm
conclusionsCompared to control, choriocapillaris and retinal CPD are reduced in DR, while FAZ area and perimeter are increased. No retinal capillary or choriocapillaris CPD changes were observed in DR eyes following anti-VEGF treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.